AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26881073 — intervention group
Group type: EXPERIMENTAL
Intervention: CANO correlation with apnea-hypopnea index (AHI)
Number of subjects: 82
Study 26881073 — intervention group
Group type: EXPERIMENTAL
Intervention: CANO correlation with nadir SpO2
Number of subjects: 82
Study 26881073 — intervention group
Group type: EXPERIMENTAL
Intervention: CANO value for screening OSA
Number of subjects: 82
Study 23640072 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1446 80 mg qd
Number of subjects: 79
Study 23640072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 23640072 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1446 (80 mg tid, 80 mg qd, 10 mg tid)
Number of subjects: 79
Study 24429244 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay
Number of subjects: 221
Study 24429244 — intervention group
Group type: COMPARATOR
Intervention: Smear microscopy
Number of subjects: 221
Study 24429244 — intervention group
Group type: COMPARATOR
Intervention: Solid culture (Löwenstein-Jensen medium)
Number of subjects: 221
Study 24429244 — intervention group
Group type: COMPARATOR
Intervention: Liquid culture (Bactec MGIT960 system)
Number of subjects: 221
Study 19847152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 2102
Study 19847152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study 18376185 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 100
Study 18376185 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 100
Study 16342198 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave electromagnetic fields (6-22 MHz) exposure before shut down
Number of subjects: 54
Study 16342198 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave electromagnetic fields (6-22 MHz) exposure after shut down
Number of subjects: 54
Study 16342198 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-wave electromagnetic fields (6-22 MHz) exposure after shut down in poor sleepers
Number of subjects: 54
Study 12699447 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 mg/day, n = 10)
Number of subjects: 20
Study 12699447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study 10680191 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal remedies
Number of subjects: 19
Study 10680191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9360565 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint position
Number of subjects: 15
Study 9360565 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 15
Study 8204673 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol education program (4-hour duration)
Number of subjects: 66
Study 8204673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate exposure group
Number of subjects: 66
Study 8204673 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exposure group
Number of subjects: 66
Study 2888509 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 161
Study 2888509 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 161
Study 2888509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 161
Study 31900204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of lopinavir/ritonavir and recombinant interferon-Î²1b with standard supportive care
Number of subjects: 0
Study 31900204 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard supportive care
Number of subjects: 0
Study 28823904 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 28
Study 28823904 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical intervention
Number of subjects: 28
Study 27619968 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioners (NPs)
Number of subjects: 12092
Study 27619968 — intervention group
Group type: COMPARATOR
Intervention: General Practitioners (GPs)
Number of subjects: 12092
Study 26617907 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous microwave ablation
Number of subjects: 90
Study 26617907 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic resection
Number of subjects: 90
Study 26617907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 90
Study 23610239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 2 mg/kg
Number of subjects: 39
Study 23610239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 6 mg/kg
Number of subjects: 39
Study 21362527 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) intervention: 16 weekly 30-minute telephone counseling sessions including motivational interviewing and individually tailored cognitive behavioral therapy.
Number of subjects: 200
Study 21362527 — intervention group
Group type: COMPARATOR
Intervention: Heart failure education (HFE) intervention: 16 weekly 30-minute telephone sessions including education and symptom monitoring.
Number of subjects: 200
Study 21362527 — intervention group
Group type: EXPERIMENTAL
Intervention: CST intervention
Number of subjects: 200
Study 18204042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (nadir P-glucose 2.7 +/- 0.5 mmol/L)
Number of subjects: 20
Study 18204042 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxaemia (nadir pO2 5.8 +/- 0.5 kPa)
Number of subjects: 20
Study 18204042 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemic normoxia (control day)
Number of subjects: 20
Study 17406167 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 100
Study 17406167 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 100
Study 14657064 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist strategy (CAS) - verapamil sustained release
Number of subjects: 22576
Study 14657064 — intervention group
Group type: COMPARATOR
Intervention: Non-calcium antagonist strategy (NCAS) - atenolol
Number of subjects: 22576
Study 11049918 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.625 mg IV)
Number of subjects: 150
Study 11049918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11049918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg IV)
Number of subjects: 150
Study 11049918 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (12.5 mg IV)
Number of subjects: 150
Study 8713784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 20% infusion (n = 5)
Number of subjects: 10
Study 8713784 — intervention group
Group type: COMPARATOR
Intervention: Dextrose 5% infusion (n = 5)
Number of subjects: 10
Study 1569339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amphotericin B (serum concentrations of 0.2-0.4 microgram/ml)
Number of subjects: 0
Study 1569339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amphotericin B
Number of subjects: 0
Study 3535521 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm of ampicillin intravenously every 6 hours until delivery
Number of subjects: 1207
Study 3535521 — intervention group
Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 1207
Study 29669617 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified mindfulness-based cognitive therapy (MBCT) course, comprising eight weekly 2-hour sessions with homework (mindfulness practice) between sessions.
Number of subjects: 22
Study 27923865 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based smoking prevention program targeting smoking-specific parenting (n=684)
Number of subjects: 1398
Study 27923865 — intervention group
Group type: COMPARATOR
Intervention: Basic information about youth smoking (Control group, n=714)
Number of subjects: 1398
Study 24955850 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish M-FAST (uncoached condition)
Number of subjects: 102
Study 24955850 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish M-FAST (coached condition)
Number of subjects: 102
Study 24955850 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish M-FAST (honest condition)
Number of subjects: 102
Study 22231543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal genital nerve (DGN) stimulation at an amplitude of 51 mA (range 30-64), pulse width: 200 μs, pulse rate: 20 Hz
Number of subjects: 7
Study 20420997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination in deltoid muscle
Number of subjects: 185
Study 20420997 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination in vastus lateralis
Number of subjects: 185
Study 18524727 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (300 mg/day)
Number of subjects: 180
Study 18524727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg/day)
Number of subjects: 180
Study 18524727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day)
Number of subjects: 180
Study 18524727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/day)
Number of subjects: 180
Study 18524727 — intervention group
Group type: COMPARATOR
Intervention: No anti-arrhythmic drugs (Control Group)
Number of subjects: 180
Study 15954962 — intervention group
Group type: EXPERIMENTAL
Intervention: NFSC (number of fluctuations in the skin conductance per second)
Number of subjects: 14
Study 15954962 — intervention group
Group type: EXPERIMENTAL
Intervention: NFSC
Number of subjects: 14
Study 12649315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12649315 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 0
Study 10608204 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg and chlorpheniramine maleate (CPM) 20 mg i.m.
Number of subjects: 60
Study 10608204 — intervention group
Group type: COMPARATOR
Intervention: Control group received 20 mg CPM i.m. alone
Number of subjects: 60
Study 8717577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush plus Ayre spatula
Number of subjects: 346
Study 8717577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervex brush
Number of subjects: 346
Study 8717577 — intervention group
Group type: COMPARATOR
Intervention: cotton swab plus Ayre spatula
Number of subjects: 346
Study 1682541 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer membrane vesicle vaccine
Number of subjects: 171800
Study 1682541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171800
Study 7023791 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of aluminum hydroxide gel (fasting)
Number of subjects: 12
Study 7023791 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml magnesium hydroxide suspension (fasting)
Number of subjects: 12
Study 7023791 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of aluminum hydroxide gel (fed)
Number of subjects: 12
Study 7023791 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of aluminum hydroxide/magnesium hydroxide mixture (fed)
Number of subjects: 12
Study 7023791 — intervention group
Group type: COMPARATOR
Intervention: Fasted, no antacid
Number of subjects: 12
Study 7023791 — intervention group
Group type: COMPARATOR
Intervention: Fed, no antacid
Number of subjects: 12
Study 31926812 — intervention group
Group type: COMPARATOR
Intervention: Bifocal‐Sham
Number of subjects: 13
Study 31926812 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiSham
Number of subjects: 13
Study 31926812 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal‐tDCS
Number of subjects: 13
Study 31926812 — intervention group
Group type: COMPARATOR
Intervention: Bifocal‐tDCS
Number of subjects: 13
Study 31926812 — intervention group
Group type: COMPARATOR
Intervention: Sham (Bifocal‐tDCS)
Number of subjects: 13
Study 31269786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh nebulizer (MN)
Number of subjects: 31
Study 31269786 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer (JN)
Number of subjects: 31
Study 28103623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (FENO) co-incubation with excess fatty acid (24hFA) in HSkMC from obese subjects
Number of subjects: 31
Study 28103623 — intervention group
Group type: COMPARATOR
Intervention: Excess fatty acid (24hFA) treatment
Number of subjects: 31
Study 28103623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment in vivo
Number of subjects: 31
Study 26374702 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous interferon (IFN) β‐1a
Number of subjects: 290
Study 24016566 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfected group (recombinant lentiviral vector encoding miR-15a/16-1)
Number of subjects: 0
Study 24016566 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfected-radiotherapy group
Number of subjects: 0
Study 24016566 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy group
Number of subjects: 0
Study 24016566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24016566 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfected group
Number of subjects: 0
Study 21632446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-impedance-guided volume management
Number of subjects: 70
Study 21632446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 50,000 U weekly for 8 doses, then 10,000 U weekly
Number of subjects: 70
Study 21632446 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 21632446 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for vitamin D(3)
Number of subjects: 70
Study 21632446 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint (death, nonfatal cardiovascular event, transfer to hemodialysis)
Number of subjects: 70
Study 21632446 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 70
Study 21632446 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 70
Study 21632446 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 70
Study 21632446 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory and fibrotic markers
Number of subjects: 70
Study 21632446 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual renal function
Number of subjects: 70
Study 20027096 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach between the peritoneum and the posterior rectus sheath (MP)
Number of subjects: 99
Study 20027096 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach between the rectus muscle and the posterior rectus sheath (MR)
Number of subjects: 99
Study 20027096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach between the rectus muscle and the posterior rectus sheath (LR)
Number of subjects: 99
Study 20027096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach between the peritoneum and the posterior rectus sheath (LP)
Number of subjects: 99
Study 20027096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach groups (LR and LP)
Number of subjects: 99
Study 20027096 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach groups (MR and MP)
Number of subjects: 99
Study 20027096 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesics
Number of subjects: 99
Study 17062774 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-treated subjects
Number of subjects: 62
Study 17062774 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 62
Study 15314531 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided training
Number of subjects: 274
Study 15314531 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 274
Study 11597802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucralfate (3 g suspension, twice a day during radiotherapy)
Number of subjects: 335
Study 11597802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day during radiotherapy)
Number of subjects: 335
Study 11597802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucralfate
Number of subjects: 335
Study 11597802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 9834047 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsant drugs (specific drugs not mentioned)
Number of subjects: 0
Study 8003559 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa 450‐750 mg/m2, busulfan 10 or 12 mg/kg, and cyclophosphamide 120 or 150 mg/kg
Number of subjects: 127
Study 8003559 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher busulfan dose
Number of subjects: 127
Study 8003559 — intervention group
Group type: EXPERIMENTAL
Intervention: Zubrod performance status of 2 or 3
Number of subjects: 127
Study 8003559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten or more previous cycles of chemotherapy
Number of subjects: 127
Study 2589355 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 25
Study 2589355 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin and azlocillin
Number of subjects: 25
Study 913868 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta‐Butazolidin (phenylbutazone 50 mg + prednisone 1.25 mg)
Number of subjects: 30
Study 913868 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 1.25 mg
Number of subjects: 30
Study 913868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30312839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 40 minutes)
Number of subjects: 39
Study 30312839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 27471840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic augmentation with retro-muscular lightweight polypropylene mesh
Number of subjects: 150
Study 27471840 — intervention group
Group type: COMPARATOR
Intervention: Conventional colostomy formation (nonmesh group)
Number of subjects: 150
Study 27471840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (mesh and nonmesh)
Number of subjects: 150
Study 25988261 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1500 mg quercetin
Number of subjects: 10
Study 25988261 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term administration of 1500 mg quercetin daily for 1 week
Number of subjects: 10
Study 25988261 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of midazolam
Number of subjects: 10
Study 22965329 — intervention group
Group type: EXPERIMENTAL
Intervention: ramosetron
Number of subjects: 123
Study 22965329 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 123
Study 22965329 — intervention group
Group type: COMPARATOR
Intervention: control (NaCl)
Number of subjects: 123
Study 22129483 — intervention group
Group type: EXPERIMENTAL
Intervention: CP children
Number of subjects: 3
Study 22129483 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 3
Study 22129483 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 3
Study 19500787 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day low-dose omeprazole infusion (3.3 mg/h)
Number of subjects: 147
Study 19500787 — intervention group
Group type: COMPARATOR
Intervention: 3-day high-dose omeprazole infusion (8 mg/h)
Number of subjects: 147
Study 19500787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study 19500787 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day low-dose omeprazole infusion
Number of subjects: 147
Study 16514327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5 mg/kg/h
Number of subjects: 0
Study 16514327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16514327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg/kg/h
Number of subjects: 0
Study 16514327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 3 mg/kg/h
Number of subjects: 0
Study 16514327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (all doses)
Number of subjects: 0
Study 12626987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 48
Study 12626987 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 48
Study 12626987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 48
Study 12626987 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve-mask
Number of subjects: 48
Study 12626987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway, Laryngeal mask airway, Combitube
Number of subjects: 48
Study 12626987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-valve-mask, Cuffed oropharyngeal airway
Number of subjects: 48
Study 12626987 — intervention group
Group type: EXPERIMENTAL
Intervention: All airway devices
Number of subjects: 48
Study 12626987 — intervention group
Group type: EXPERIMENTAL
Intervention: All airway devices with 100% oxygen
Number of subjects: 48
Study 11085201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 to 300 mg/day for 6 to 10 weeks
Number of subjects: 0
Study 11085201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine ≤300 mg/day for 6 to 8 weeks
Number of subjects: 0
Study 11085201 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine ≤300 mg/day for ≥8 weeks
Number of subjects: 0
Study 11085201 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 0
Study 9200054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 2
Study 9200054 — intervention group
Group type: COMPARATOR
Intervention: Control (unscreened population)
Number of subjects: 2
Study 8397881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol subjects received sufficient alcohol to raise their blood alcohol level to .07 mg %
Number of subjects: 96
Study 8397881 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 96
Study 8397881 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak intoxication level
Number of subjects: 96
Study 3453187 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics (mainly chlorthalidone)
Number of subjects: 7006